AN EXPRESSION CASSATTE FOR PRODUCING A SINGLE-STRANDED NUCLEIC ACID PHARMACEUTICALLY ACCEPTED COMPOSiTION HAVING SAID EXPRESSION CASSATTE AND METHOD OF PRODUCING A SINGLE-STRANDED DNA INSIDE A EUKARYOTIC CELL BY INTRODUCTION OF SAID EXPRESSION CASSATTE
Application IN/PCT/2002/00430 published 2006-04-07, filed 2002-04-03
A methods for altering expression of a target nucleic acid sequence in a target cell by production of single-stranded cDNA (ss-cDNA) in the target cell in vivo. The target cell is transfected with a cassette comprising a sequence of interest, an inverted tandem repeat, and a primer binding site 3' to the inverted tandem repeat. Transcription of the cassette by the target cell produces an RNA template which is reverse transcribed to produce ss-cDNA of a specified sequence. A reverse transcriptase/RNAse H coding gene may also be transfected into the target cell. The ss-cDNA is modified to remove all flanking vector sequences by taking advantage of the "stem-loop" structure of the ss-cDNA, which forms as a result of the inverted tandem repeat that allows the ss-cDNA to fold back on itself, forming a double stranded DNA stem. The double-stranded stem contains one or more restriction endonuclease recognition sites and the loop, which remains as ssDNA, is comprised of the sequence of interest, which can be any desired nucleotide sequence. This design allows the double-stranded stem of the stem-loop intermediate to be cleaved by the desired corresponding restriction endonuclease(s) and the loop portion, or sequence of interest, is then released as a linearized, single-stranded piece of DNA. This released (or cleaved) ssDNA piece contains minimal, if any, sequence information either upstream 5' or downstream 3' from the double stranded stem. The resulting ssDNA binds to an endogenous target nucleic acid sequence to alter the expression of that sequence for such therapeutic purposes as gene inactivation using duplex or triplex binding of nucleic acids, site-directed mutagenesis, interruption of cellular function by binding to specific cellular proteins, and interfering with RNA splicing functions. (FIG. - 3)
Applicant
CYTOGENIX INC
9881 SOUTH WILCREST HOUSTON TX 77099 USA
Inventor
CONRAD CHARLES A CHEN YIN
International Info
Classification: C12N 15/10,15/11,15/63
Publication Number: WO 01/25419 A1
Application Date: 2000-10-04
Priority Information
09/411,568 US 1999-10-04